Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Treatment Options and Continuity of Care in MAFLD
Author(s): Carmen Lara-Romero , Manuel Romero-Gómez Added: 11 months ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
AHA 24: New Insights from CLEAR OUTCOMES
Author(s): Marc P Bonaca Added: 5 months ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,… View more

Vascular Disease and Surgery

Prevention & Chronic Conditions
Links between NAFLD/NASH and Cardiometabolic Syndrome
Author(s): Sheila Gato , Vanessa García-Fernández , Antonio Gil-Gómez , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Luis Castilla-Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Remnant Lipoproteins and ASCVD
Author(s): Mohanad Gabani , Michael D Shapiro , Peter P Toth Added: 1 year ago

Prevention & Chronic Conditions
Job title: Director
Andrew Mente
Job title: Associate Professor – Department of Health Research Methods, Evidence, and Impact (HEI)
Dr Andrew Mente is a Principal Investigator for the Epidemiology program at the Population Health Research Institute and Associate Professor – Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University. Dr Mente received his doctoral degree in Epidemiology from the University of Toronto and completed post-doctoral training in cardiovascular epidemiology at McMaster… View more
Clinical Management of Non-alcoholic Steatohepatitis
Author(s): Carlos Millán-Rodríguez , Carlos Palacios Castelló , María de Regla Caballero-Valderrama , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
EASD 23: Efinopegdutide in NAFLD & T2D patients
Author(s): Samuel S Engel Added: 1 year ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Author(s): Antonio Ceriello , Ileana L Piña , Gianluigi Savarese , et al Start date: Mar 23, 2024

Heart Failure

Prevention & Chronic Conditions